XagenaNewsletter
Xagena Mappa
Medical Meeting
Dermabase.it

ASCO20 Virtual Meeting -News - Parte 1


Report presentati al Congresso Virtuale ASCO ( American Society of Clinical Oncology ) 2020:

Primary analysis of CITYSCAPE study of the anti-TIGIT antibody Tiragolumab plus Atezolizumab versus Atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC

The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple cancers, including non-small-cell lung cancer ( NSCLC ). In a phas ...


Ibrutinib, a Bruton’s tyrosine kinase inhibitor, in combination with PD-1 inhibitor Nivolumab in patients with metastatic solid tumors

Myeloid-derived suppressor cells ( MDSC ) are expanded in cancer and promote immune suppression. A research has shown that Ibrutinib ( Imbruvica ) inhibits migration and immunosuppressive function o ...


Efficacy and safety of Entrectinib in patients with NTRK-fusion positive solid tumors: updated integrated analysis

NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib ( Rozlytrek ) is a potent inhibitor of TRKA/B/C. In phase 1/2 studies ( ALKA, STARTRK ...


Apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer: final survival results from SPARTAN, a phase III trial

SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and a prostate-specific antigen ( PSA ) doubling time of les ...


Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer: results from GEOMETRY mono-1 study

In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell lung cancer ( NSCLC ) patients who were pretreated ( cohort 4 ) ...


Cabozantinib post-immunotherapy in patients with advanced renal cell carcinoma: a pooled analysis of efficacy and safety

While studies have demonstrated survival benefits of first-line regimens including immuno-oncology agents ( IO ) in advanced renal cell carcinoma ( aRCC ), optimal treatment following onco-immunothera ...


First-line Pembrolizumab monotherapy in advanced non-clear cell renal cell carcinoma: updated follow-up for KEYNOTE-427 cohort B

KEYNOTE-427, a single-arm, open-label, phase 2 study, has shown antitumor activity with first-line Pembrolizumab ( Keytruda ) monotherapy in non-clear cell renal cell carcinoma ( nccRCC ) ( cohort B ) ...


Olaparib in patients with pancreatic cancer with BRCA1/2 inactivating mutations: results from TAPUR study

TAPUR ( Targeted Agent and Profiling Utilization Registry ) is a phase II basket study evaluating anti-tumor activity of targeted agents in patients with advanced cancers with genomic alterations. R ...


First-line treatment of EGFR-mutated non-small cell lung cancer: concurrent Osimertinib plus Gefitinib

First-line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) is standard of care for patients with EGFR-mutated non-small-cell lung cancer ( NSCLC ). The EGFR TKI Osimertinib ( Tagrisso ) is ...


Cabozantinib in combination with Atezolizumab in patients with metastatic castration-resistant prostate cancer: results of cohort 6 of the COSMIC-021 trial

Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and has shown encouraging activity in combination with ICIs ...





Indietro